A leading cannabis company, Aurora Cannabis Inc., has disclosed its willingness to entertain an acquisition proposal from a U.S.-based cannabis firm eyeing a takeover of the Edmonton-headquartered company. Following the revelation by Curaleaf Holdings Inc. that it intended to acquire all shares of Aurora, the latter announced the establishment of a special committee to review the unsolicited offer.

Curaleaf, a company based in Stamford, Connecticut, and listed on the Toronto Stock Exchange, expressed its intention to create a unified cannabis entity spanning 17 countries across Europe, North America, and other global markets through the potential merger. Despite attempting private negotiations with Aurora’s leadership without success, Curaleaf decided to publicly disclose its proposal after Aurora’s board declined to engage in discussions following formal letters of intent sent on June 23 and July 7 by Curaleaf’s CEO, Boris Jordan.

In response, Aurora disputed Curaleaf’s assertion that it had rebuffed the offer, citing ongoing communication between the lead independent director and Curaleaf’s CEO up to July 24. Aurora plans to establish a special committee comprising independent directors to assess the proposal’s alignment with stakeholder interests, noting that the outcome of the review is uncertain, and business operations will continue as usual in the interim.

While acknowledging Curaleaf’s interest, analysts from TD Cowen cautioned that the current offer undervalues Aurora’s long-term prospects. They emphasized Aurora’s market leadership, product quality, financial strength, and regulatory expertise as factors that could drive substantial future value creation.

Curaleaf’s CEO, Boris Jordan, highlighted the potential for value creation through the integration of Curaleaf’s global distribution capabilities with Aurora’s established international medical cannabis presence and production capacity. The companies’ combined revenue exceeding $1.5 billion US over the past year is expected to yield significant annual cost savings post-acquisition, with Curaleaf projecting at least $40 million US in synergies.

Jordan emphasized that the proposed merger offers a mutually beneficial opportunity for shareholders of both companies, providing Aurora shareholders with broader exposure to the global cannabis market and favorable regulatory trends in the U.S.